Hansen Clinic

Call Today! (480) 991-5092.

Schedule an Appointment

The Future of Medicine Today

by | Jan 9, 2015

Print Friendly, PDF & Email

On December 11-13, 2014, Dr. and Mrs Hansen attended the World Congress on Anti-Aging Medicine in Las Vegas, Nevada. The theme of this Medical Conference was entitled, “The Future of Medicine Today.” The most exciting topics at the Conference focused on using Platelet Rich plasma to bring Cellular Therapy into the office this year. Cellular Therapy in here now for every patient who wants to revive aging connective tissue and restore youthful ligaments, tendons, cartilage and skin. To learn more click here.
Dr. Hansen is one of only 26,000 Physicians that are practicing members of the American Academy of Anti-Aging Medicine, out of 893,851 total practicing physicians in the U.S., from all specialties.

Here are a few highlights from the 22nd Annual World Congress on Anti-Aging Medicine

  • Platelet Rich Plasma (PRP) Regenerates Connective Tissue and Increases IGF-1 (Growth Hormone)
  • Exercise Increases Stem Cells by as much as 25%
  • Insulin, from eating too much sugar, blocks Growth Hormone, the natural Collagen building hormone
  • There are 2 million Joint Replacement Surgeries each year in the U.S.
  • Joint Replacement Surgery causes a 25-30 times Increased Risk of Heart Attack
  • Stem Cells are made by the body to repair or replace worn out cells
  • Without Stem Cells we would all die within 2-3 days
  • PRP has been used for 20 years
  • Burn-out Syndrome is caused by multi-hormone deficiency
  • Fatigue, Depression, Anxiety, Arthritis, and poor resistance to noise = DHEA Deficiency
  • Constant & Prolonged Fatigue is caused by Deficiency of all 3 Sex Hormones (Testosterone, Progesterone and Estrogens)
  • PRP can be used to reverse hair loss
  • Older men who secrete the highest Adrenaline levels are the most likely to develop Alzheimer’s Disease
  • Pregnenolone, Estriol and Progesterone regenerate nerve tissue, improve memory and prevent amyloid plaque in the brain that is associated with Alzheimer’s disease
  • Osteoporosis is due to Vitamin C deficiency not Calcium
  • Intracellular Calcium + Iron causes Malignant Cell Transformation
  • High levels of intracellular Calcium causes Cell death seen in patients with Alzheimer’s Parkinson’s and ALS
  • The higher the Coronary Calcium Score the higher the risk of Death from ALL Causes
  • Optimal Testosterone level in Women Significantly Reduces Breast Cancer Risk
  • Low Testosterone in men and women Increases Risk of Coronary Artery Disease

 
Every year I attend at least 30 hours of Continuing Medical Education Courses with each of you in mind. I take lots of notes and I actually write your names down as you come to mind when a specificly aplicable nutrient, hormone, remedy, treatment, or new breakthrough is mentioned that strikes me as something that I should consider for you. I look forward to sharing what I have recently learned with you all. Please make sure to watch for my Vital Health Newsletter each month and let me know if you have specific questions, concerns, or recipes, etc that you would like to share with me and or all of the Hansen Clinic community. Sincerely, Clark Hansen, N.M.D.    

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Click Here to see the full Report of the Research
Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Join Our Community

Call to Schedule Your Appointment Today! (480) 991-5092.

Receive Our Newsletter

7 + 15 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });